893 results about "Hepatic fibrosis" patented technology

The object of the present invention is to provide PPAR (peroxisome proliferator-activated receptor) activity regulators, which can be widely used for improving insulin resistance and preventing / treating various diseases such as diabetes, metabolic syndromes, hyperlipemia, high-blood pressure, vascular disorders, inflammation, hepatitis, fatty liver, liver fibrosis, NASH (non-alcoholic steatohepatitis) and obesity.The present invention provides PPAR activity regulators which comprise an acylamide compound having the specific structure, prodrugs thereof, or pharmaceutically acceptable salts thereof.

The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and / or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).

The invention is related to methods of preventing and treating hepatic fibrosis using A2B adenosine receptor antagonists and utility in the treatment and prevention of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases. The invention also relates to pharmaceutical compositions for use in the method.

The invention belongs to the technical field of molecular biology and relates to application of an exosome derived from human mesenchymal stem cells to preparation of medicines for antagonizing scars or tissue and organ fibrosis. According to the application, the high-purity and high-bioactivity exosome is obtained by subjecting healthy human umbilical cords to primary in-vitro culture, collecting liquid supernatant after amplification, performing low-temperature ultracentrifugation, purifying and the like; the exosome is used individually or added into medicines, health care products and cosmetics according to a proportion to be developed into a product with a bioactivity function, thereby being capable of regulating organism cell signal transduction effectively, inhibiting fibrocyte differentiation and then antagonizing the tissue and organ fibrosis and scar forming. Through experimental verification, the exosome can play a remarkable role in repairing promotion in hypertrophic scar after skin injury, particularly pathological fibrosis proliferation such as scar contracture of the joint parts, hepatic fibrosis and cardiac fibrosis, and is high in safety, little in toxicity and convenient to storage and transport, thereby being wide in application prospect.

Disclosed are δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide compounds of formula (I)and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

The invention discloses a human umbilical cord mesenchymal stem cell (HUMSC) anti-hepatic fibrosis injection and a preparation method thereof. The injection is composed of 10%-50% of human albumin stock solution, 49.5%-89.5% of acetated Ringer's solution and 0.5% of heparin calcium, wherein, the concentration of the human albumin stock solution is 10%, and 1ml of the injection contains 6*10<5>-7*10<5> HUMSCs. The preparation method comprises the following steps: providing an MSC preserving fluid and pre-cooling the MSC preserving fluid for later use, wherein, the MSC preserving fluid comprises the human albumin stock solution, the Acetated Ringer's solution and the heparin calcium; providing the HUMSCs and adding the HUMSCs to the MSC preserving fluid; and adjusting the number of the HUMSCs added to the MSC preserving fluid to be 6*10<5>-7*10<5> HUMSCs / ml by means of re-suspending. The injection provided by the invention has the advantages of obvious curative effect and high stability, and is convenient in storage and transport and safe in use, thus being capable of bringing gospel to patients with hepatic fibrosis.

The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and / or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).

The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and / or proliferation of liver cells, such as liver fibrosis or fatty liver disease.

The invention discloses an FXR receptor modulator, and a preparation method and an application thereof, belonging to the field of medicinal chemistry. The FXR receptor modulator with a structure characteristic as shown in a formula I in the specification or pharmaceutically-acceptable salts or stereoisomers or solvates or prodrugs thereof can bind with an FXR (i.e., NR1H4) receptor and is used as an agonist or a partial agonist of the FXR receptor, thereby being able to be applied to prevention and treatment of FXR mediated diseases, such as chronic intrahepatic or extrahepatic cholestasis, hepatic fibrosis caused by chronic cholestasis or acute intrahepatic cholestasis, or chronic hepatitis B, or gallstone, or liver cancer, or colon cancer, or inflammatory bowel diseases, etc., wherein a part of compounds specifically can reach an FXR-excited EC<50> of 100 nM or below, show good FXR agonist activity, have excellent application prospects, and provide a new medicine choice for clinical treatment of the FXR mediated diseases.

The invention relates to the technical field of compound traditional Chinese preparations, and in particular relates to a quality control method of liuwei wuling tablets. The quality control method is characterized in that 20 different proportion groups are formed by randomly sampling six medicinal materials of the liuwei wuling tablets; a corresponding HPLC fingerprint spectrum is established, and in-vitro anti-hepatic fibrosis activity is measured; and an SPSS software is utilized to analyze, so that a pectrum-effect relationship of in-vitro anti-hepatic fibrosis effect of the liuwei wuling tablets is established. The relatively perfect quality control method is established on the basis of pharmacodynamic substances of the liuwei wuling tablets. Compared with a conventional single-index content measuring method, the quality control method is more comprehensive, scientific and standard, and has the advantages that the content of multiple components is simultaneously measured, so that not only the analysis time is shortened, but also the loss of a solvent is saved.

The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and / or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).

The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and / or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).

The invention discloses a tripterine derivative, biogenetic salt of the derivative, and a preparation method and application of the biogenetic salt. The tripterine has a structure as shown in the specification. The biogenetic salt of the tripterine derivative is prepared by mixing and reacting the tripterine derivative with medicinally acceptable inorganic acid or organic acid. The tripterine derivative and the biogenetic salt of the tripterine derivative can be used for preparing medicines for resisting hepatic fibrosis. A nitrogen-containing hydrophilic group is introduced into C-28 position carboxylic acid and the tripterine derivative is salinized, so that the pharmacokinetic property is improved obviously, the bioavailability is improved, and the safety is improved.

The present invention provides N-substituted-2(1H) pyridones or the pharmaceutical acceptable salts thereof, and the pharmaceutical preparations containing the compounds. The compounds of the present invention can be used to treat various fibrotic diseases effectively, e.g., hepatic fibrosis.

Inflammatory disorders, including obliterative airway disease, renal fibrosis, diabetic nephropathy, and liver fibrosis are treated with immunosuppressive triptolide compounds, in particular triptolide compounds effective to inhibit TGF-β production in a patient afflicted with such a disorder.

This invention relates to natual medicine chemical and medical technique field. It discloses two kind celosin new compounds of celosin A and celosin B structure and its distillation and eperating method from amaranthcea plant celosin. Their chemical general formula is shown as formula (1). This invention also discloses the compound and its derivative medicine aspect application of curing and preventing fatty liver, liver injury, hepatic fibrosis, liver cirrhosis, coronary heart disease, cardiac infarction, myocardial ischemia, cerebral ischemia, cerebral infarction, cerebral apoplexy, diabetes mellitus, hyperinsulinism, insulin resistance disease, obesity, glucose intolerance capability, and / or hypertension adiposity, hyperlipemia, dementia, depression or anxiety, and insomnia diseases.

The invention provides a magnetic particle chemiluminescence method III type procollagen N-terminal peptide quantitative measurement kit and a preparation method thereof. The kit is composed of PIIINP magnetic particles, tracing conjugate for measuring PIIINP, and a quality control substance. The invention also provides a preparation method of the quantitative measurement kit. The preparation method adopts a micro particle chemiluminescence immunoassay technology, an automatic chemiluminescence method is used to carry out detection, the operation time is reduced, the artificial operation error is reduced, the detection precision and accuracy are improved, and the kit is suitable for assisted diagnosis of early stage hepatic fibrosis in clinic.

A composition for treating hepatic fibrosis and a method of using and manufacturing the composition are provided. The composition includes a quinazolinone derivative, preferably Halofuginone.

The invention discloses a preparation method of spanishneedles herb total flavonoids, which can be obtained by the following steps: the spanishneedles herb is extracted through ethanol reflux; minimum quantity of ethanol is recovered, impurities are removed by standing and organic solvent is used for defatting; then mixed solvent is extracted beneficiation and resin purification, thus spanishneedles herb total flavonoids is obtained. The obtained flavone extract has high flavone content, over 50%. With simple and feasible technique, and high extract yield rate, the invention is suitable for industrialized production. The total flavonoid extract obtained from the invention has the effect of reducing blood pressure, blood lipid and blood sugar, anti-oxidation and preventing hepatic fibrosis, which can prepare drugs for treating cardiovascular diseases, reducing blood pressure, blood lipid and blood sugar as well as preventing haptic fibrosis.

The invention provides a stem cell preparation for treating hepatic fibrosis, and a preparation method of the stem cell preparation. The stem cell preparation for treating hepatic fibrosis is prepared from human menstrual blood mesenchymal stem cells, a chemotactic factor CXCL8 and normal saline. The obtaining method of the menstrual blood mesenchymal stem cells is simple, free of ethical restriction, high in cell viability and high in proliferation capacity, has multi-directional differentiation potential and is simple and convenient to prepare. The menstrual blood mesenchymal stem cell preparation infusion technology provided by the invention is simple and convenient to operate; the hepatic fibrosis is treated by virtue of the menstrual blood mesenchymal stem cells; and the developed preparation method of the stem cell preparation for treating the hepatic fibrosis has very important clinical significance and wide application prospect.

Methods for diagnosis of fibrotic diseases, staging of fibrotic diseases and monitoring treatment of fibrosis. The presence of fibrotic tissue is detected. First, a T1ρ relaxation time of tissue is determined using magnetic resonance imaging. The determined T1ρ relaxation time is then compared to a baseline T1ρ relaxation time indicative of healthy tissue, and the presence of fibrotic tissue is then determined based on results of said comparison step. To determine a stage of fibrosis, a T1ρ relaxation time of tissue is determined and compared to one or more calibrated T1ρ relaxation times indicative of one or more stages of fibrosis, and the stage of fibrosis is determined based on results of said comparison step. The proposed technology offers a non-invasive MRI technique based on T1ρ contrast that is sensitive enough to detect small changes of ECM hepatic protein concentration and architecture in all stages of hepatic fibrosis.

A method for the treatment of hepatic fibrotic injuries caused by various diseases, viral infections or toxic agents which involves the use of glatiramer acetate as an immuno-modulatory agent. The diseases to be treated are hepatic fibrosis and hepatic cellular carcinomas. Also disclose is the use of glatiramer acetate in the treatment of inflammatory bowel diseases. Additionally, disclosed are methods for screening for immuno-modulatory agents which are useful in the treatment of hepatic fibrosis, hepatic cellular carcinomas and inflammatory bowel diseases.

The instant invention relates to a process for the preparation of a pharmaceutical composition in sustained-release tablet form comprising from 600 milligrams to 2400 milligrams of Pirfenidone (PFD), in such a way that the drug is bioavailable during an extended period of time of 12 hours from its administration. In this way, the anti-fibrotic and anti-inflammatory action of the drug Pirfenidone is optimized. Moreover, the instant invention offers advantages and a higher therapeutic efficacy compared to other pharmaceutical forms of Pirfenidone for oral administration and its therapeutic application in the regression of chronic renal failure secondary to primary glomerulosclerosis; it shows a better activity with regard to the reduction and / or regression of deleterious effects in breast capsular contracture observed after the surgical implantation of breast implants in humans and has an important anti-TNF-α and anti-TGF-β1 action for the treatment of hepatic fibrosis.

The invention is related to methods of treating hepatic fibrosis using A2B adenosine receptor antagonists and utility in the treatment of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases.

The invention discloses hepatic fibrosis detection system, relating to the technical field of hepatic fibrosis research. The hepatic fibrosis detection system comprises a transient elastography device an input device, a classifier and an output device, wherein the input device is used for receiving ages and serum biochemical indicators, and the serum biochemical indicators at least comprise blood platelet, hyaluronic acid (HA), serum direct bilirubin (DBIL), prothrombin time (PT), alanine aminotransferase / serum glutamic pyruvic transaminase (ALT; GPT), and aspartate transaminase / serum glutamic oxalacetic transaminase (AST; GOT); the classifier is used for performing hepatic fibrosis staging according to the ages and the serum biochemical indicators and received by the input device and transient elasticity imaging data; and the output device is used for outputting of hepatic fibrosis staging results of the classifier. The hepatic fibrosis detection system of the embodiment disclosed by the invention has the advantages of noninvasiveness, strong practicability, simple and convenient method, low price, good safety and the like.

A Chinese medicine in the form of honeyed pills for treating chronic hepatism and hepatic fibrosis is prepared from 13 Chinese-medicinal materials including saffron, red sage root, astragalus root, Chinese angelica root, etc through cleaning, pulverizing, sieving, proportionally mixing, adding honey, pilling and Co-60 sterilizing. Its advantage is high curative effect up to 94%.